ZYN002

DRUG2 trials

Sponsors

Harmony Biosciences Management, Inc.

Conditions

22Q11.2 Deletion SyndromeFragile X SyndromeFragile X Syndrome (FXS)

Phase 2

Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE)

CompletedNCT05149898

Harmony Biosciences Management, Inc.22Q11.2 Deletion Syndrome

Start: 2020-02-19End: 2022-11-09Updated: 2026-03-09

Phase 3

Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome

CompletedNCT04977986

Harmony Biosciences Management, Inc.Fragile X Syndrome, Fragile X Syndrome (FXS)

Start: 2021-09-13End: 2025-08-29Updated: 2026-09-01

Related Papers

Phase 2, open-label INSPIRE trial to assess the tolerability and effectiveness of transdermal cannabidiol gel in children and adolescents with 22q11.2 deletion syndrome (ZYN2-CL-031)

Journal of Neurodevelopmental Disorders2026-03-26

A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)

Journal of Neurodevelopmental Disorders2022-11-2560 citations